Patents Examined by Jeanine A. Goldberg
  • Patent number: 9976187
    Abstract: Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: May 22, 2018
    Inventors: Vladimir Bajic, Hicham Mansour, Roberto Incitti
  • Patent number: 9970061
    Abstract: The present invention compositions, methods and systems to identify, detect, and/or quantify bacterial DNA in the presence of contaminating non-bacterial DNA. In particular, the present invention provides oligonucleotides configured to detect a relatively small amount of bacterial DNA in the presence of an overwhelmingly large amount of contaminating human DNA.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: May 15, 2018
    Inventors: David J. Ecker, Steven A. Hofstadler, Rangarajan Sampath, Lawrence B. Blyn, Thomas A. Hall, Mark W. Eshoo
  • Patent number: 9944985
    Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: April 17, 2018
    Assignee: Children's Hospital Medical Center
    Inventors: Senthilkumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jarolsaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda
  • Patent number: 9926600
    Abstract: Compositions and methods for the detection and treatment of T1D are provided.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: March 27, 2018
    Inventors: Hakon Hakonarson, Joseph Glessner, Struan F. A. Grant, Constantin Polychronakos
  • Patent number: 9926599
    Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein the method comprises analyzing the bisulfite convertibility of at least one CpG position in the CD3+CD4+ T helper cell specific non-methylated bisulfite convertible region according to SEQ ID No. 1, wherein a bisulfite convertibility of at least one CpG position to at least 90%, preferably to at least 91% and more preferably to at least 92% and most preferred to at least 95% in the sample is indicative for a CD4+ T-lymphocyte cell, in particular a CD3+CD4+ T-lymphocyte cell. The present invention further relates to analyzing the bisulfite convertibility of at least one CpG position in the genes FLJ00060, FLJ38379, PPP6C, CD226, ZBTB7B and TNFAIP8 that are capable of positively identifying CD4 expressing cells in whole blood and segregate between CD4 and CD8 positive CD3 positive cells.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: March 27, 2018
    Assignee: EPIONTIS GMBH
    Inventor: Sven Olek
  • Patent number: 9909191
    Abstract: Described herein is a set of oligonucleotide probes. Also included are methods of using the oligonucleotide probes in profiling the microbiota of the GI tract of a subject and methods of diagnosing or monitoring a disease or condition in a subject or predicting or assessing the risk of a subject developing a disease or condition. Kits comprising the oligonucleotide probe set described herein are also provided.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: March 6, 2018
    Inventors: Heidi Vebø, Knut Rudi, Monika Sekelja
  • Patent number: 9909184
    Abstract: Disclosed are methods, compositions, and diagnostic kits for the rapid detection of certain types of ?-thalassemia and ?-thalassemia. In some embodiments, a diagnostic kit, reagents, and methods are disclosed for the rapid detection of various ?-thalassemia and ?-thalassemia genotypes in multiple patient samples using real-time PCR. More specifically, in certain embodiments, diagnostic kits, reagents, and methods are disclosed for the rapid detection of up to seven different ?-thalassemia genotypes and twenty different ?-thalassemia genotypes in one single multiplex real-time PCR reaction.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: March 6, 2018
    Assignee: URIT Medical Electronic Co., Ltd.
    Inventors: Tom Cheng Xu, Jun Liu, Chengfeng Jiang, Jinlan Xu, Lili Sun
  • Patent number: 9902991
    Abstract: The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: February 27, 2018
    Assignee: GENOMIC HEALTH, INC.
    Inventors: Dominick Sinicropi, John Morlan
  • Patent number: 9896729
    Abstract: The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: February 20, 2018
    Assignees: The University of Manchester, National Institute of Aging, Hospital District of Helsinki and UUSIMAA, VU University Medical Centre Armsterdam, UCL Business PLC, University College Cardiff Consultants Limited
    Inventors: Stuart Pickering-Brown, Bryan Traynor, Andrew B. Singleton, Huw Morris, Peter Heutink, John Hardy, Pentti Tienari
  • Patent number: 9890432
    Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions and HPV-induced invasive cancers, said method comprising detection of hypermethylation in the PRDM14 and/or FAM19A4 gene in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential and HPV-induced invasive cancers. The invention further comprises the use of the PRDM14 and/or FAM19A4 gene in such a method and a testkit for the detection of PRDM14 and/or FAM19A4 methylation.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: February 13, 2018
    Assignee: SELF-SCREEN B.V.
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen
  • Patent number: 9868990
    Abstract: The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: January 16, 2018
    Assignees: The Regents of the University of Michigan, The Trustees of the University of Pennsylvania
    Inventors: John K. Fink, Shirley Rainier, Robert D. Nicholls, Jinghua Chai
  • Patent number: 9862999
    Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: January 9, 2018
    Assignee: The Chinese University of Hong Kong
    Inventors: Yuk Ming Dennis Lo, Wai Kwun Rossa Chiu, Stephen Siu-Chung Chim, Yu-Kwan Tong, Chunming Ding
  • Patent number: 9856538
    Abstract: The present disclosure provides methods, kits, and primers for analyzing AHASL genes of plants, including wheat. The methods, kits, and primers of the present disclosure can make use of forward AHASL primers designed without use of software or other assay-design technology and can be used in a real-time PCR assay to determine the zygosity of AHASL genes encoding AHAS enzymes providing tolerance to AHAS enzyme inhibitors.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: January 2, 2018
    Assignee: BASF Agrochemical Products B.V.
    Inventors: Sherry Whitt, Cory Rodgers
  • Patent number: 9850544
    Abstract: We examined IQGAP1 copy gain and its relationship with clinicopathologic outcomes of thyroid cancer and investigated its role in cell invasion and molecules involved in the process. We found IQGAP1 copy number (CN) gain?3 in 1 of 30 (3%) of benign thyroid tumor, 24 of 74 (32%) follicular variant papillary thyroid cancer (FVPTC), 44 of 107 (41%) follicular thyroid cancer (FTC), 8 of 16 (50%) tall cell papillary thyroid cancer (PTC), and 27 of 41 (66%) anaplastic thyroid cancer, in increasing order of invasiveness of these tumors. A similar tumor distribution trend of CN?4 was also seen. IQGAP1 copy gain was positively correlated with IQGAP1 protein expression. It was significantly associated with extrathyroidal and vascular invasion of FVPTC and FTC and, remarkably, a 50%-60% rate of multifocality and recurrence of BRAF mutation-positive PTC (P=0.01 and 0.02, respectively). The siRNA knockdown of IQGAP1 dramatically inhibited thyroid cancer cell invasion and colony formation.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: December 26, 2017
    Assignee: The Johns Hopkins University
    Inventor: Michael Mingzhao Xing
  • Patent number: 9845506
    Abstract: A method for determining the prognosis of prostate cancer in a subject is provided which comprises the assessment of the methylation status of the HSPB1 gene in a prostate cancer sample.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: December 19, 2017
    Assignee: Queen Mary University of London
    Inventors: Attila Lorincz, Natasa Vasiljevic, Amar Ahmad
  • Patent number: 9840740
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: December 12, 2017
    Inventors: Matthew J. McGinniss, Arlene M. Buller, Franklin Quan, Mei Peng, Weimin Sun
  • Patent number: 9809860
    Abstract: This invention relates to test kits and methods for their use in determining the expression levels of genetic markers. Additionally, this invention relates to kits and uses thereof for the determination of ratios of genetic markers. Ratios of genetic markers can be used to assist in analysis of bladder cancer from samples of urine.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: November 7, 2017
    Assignee: Pacific Edge Limited
    Inventor: Parry John Guilford
  • Patent number: 9771621
    Abstract: The present invention relates to method and kit for performing a colorectal cancer assay. Especially a method including extracting total RNA from a peripheral blood sample obtained from a patient suspected of having or having colorectal cancer; contacting the total RNA, or cDNA or cRNA obtained from the total RNA, with one or more reagents specific for at least one target gene and no more than 100 target genes; and measuring the expression level of the at least one target gene and no more than 100 target genes. The at least one target gene and no more than 100 target genes includes one or more members selected from the group consisting of the KLRB1, KLRC2, KLRC3, KLRD1, KLRK1, CD247, RRAS2, SH2D1B, LCK, MRPS6, SPRY4, CYBB, DUSP2, PDE4D, SH2D2A, GZMB, INSR, ITGAM, VCAN, CD163, P2RY10, CD226, MRPL10, ITPRIPL2, CD2, and NUDT16 genes.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: September 26, 2017
    Assignee: BIOMERIEUX
    Inventors: Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin, Fang Liu
  • Patent number: 9771611
    Abstract: The invention relates to a method for detecting several different chromosomes or DNA regions in a cell in order to provide evidence for structural chromosomal aberrations, wherein the chromosomal aberrations have at least two breaking point regions within a chromosome, on the basis of directly or indirectly labeled nucleic acid fragments (probes), wherein: a first probe labeled with label A (probe A) and a second probe labeled with label B (probe B) flank a breaking point region 1, and form the fusion signals A-B; and two probes, a third and a fourth, each labeled with a label C (probes C), flank a breaking point region 2, and form the fusion signals C-C, wherein the above-mentioned fusion signals change in the event of a chromosomal aberration to fusion signals A-C and to fusion signals B-C.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: September 26, 2017
    Assignee: Zytovision GmbH
    Inventor: Sven Hauke
  • Patent number: 9765405
    Abstract: This invention is related to novel PNA probes, probe sets, methods and kits pertaining to the detection of one or more species of Candida yeast. Non-limiting examples of probing nucleobase sequences that can be used for the probes of this invention can be selected from the group consisting of: AGA-GAG-CAG-CAT-GCA (Seq. Id. No. 1), AGA-GAG-CAA-CAT-GCA (Seq. Id. No. 2), ACA-GCA-GAA-GCC-GTG (Seq. Id. No. 3), CAT-AAA-TGG-CTA-CCA-GA (Seq. Id. No. 4), CAT-AAA-TGG-CTA-CCC-AG (Seq. Id. No. 5), ACT-TGG-AGT-CGA-TAG (Seq. Id. No. 6), CCA-AGG-CTT-ATA-CTC-GC (Seq. Id. No. 7), CCC-CTG-AAT-CGG-GAT (Seq. Id. No. 8), GAC-GCC-AAA-GAC-GCC (Seq. Id. No. 9), ATC-GTC-AGA-GGC-TAT-AA (Seq. Id. No. 10), TAG-CCA-GAA-GAA-AGG (Seq. Id. No. 11), CAT-AAA-TGG-CTA-GCC-AG (Seq. Id. No. 12), CTC-CGA-TGT-GAC-TGC-G (Seq. Id. No. 13), TCC-CAG-ACT-GCT-CGG (Seq. Id. No. 14), TCC-AAG-AGG-TCG-AGA (Seq. Id. No. 15), GCC-AAG-CCA-CAA-GGA (Seq. Id. No. 16), GCC-GCC-AAG-CCA-CA (Seq. Id. No. 17), GGA-CTT-GGG-GTT-AG (Seq. Id. No.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: September 19, 2017
    Assignee: Applied Biosystems, LLC
    Inventors: Jens J. Hyldig-Nielsen, Henrik Stender, Kenneth M. Oliveira, Susan Rigby